United States - English - NLM (National Library of Medicine)

biomedical research foundation of northwest louisiana - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation d

United States - English - NLM (National Library of Medicine)

wisconsin medical radiopharmacy, llc - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f 18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data ). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose

United States - English - NLM (National Library of Medicine)

houston cyclotron partners lp dba cyclotope - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 500 mci in 1 ml - fludeoxyglucose f 18 injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (pet) imaging. the active ingredient 2-deoxy-2-[ 18 f]fluoro-d-glucose has the molecular formula of c 6 h 11 18 fo 5 with a molecular weight of 181.26, and has the following chemical structure: fludeoxyglucose f 18 injection is provided as a ready to use sterile, pyrogen free, clear, colorless citrate buffered solution. each ml contains between 0.740 to 18.5 gbq (20.0-500 mci) of 2-deoxy-2-[ 18 f]fluoro-d-glucose at the eos, 4.5 mg of sodium chloride in citrate buffer. the ph of the solution is between 4.5 and 7.5. the solution is packaged in a multiple-dose glass vial and does not contain any preservative. fluorine f 18 has a physical half-life of 109.7 minutes and decays to oxygen o 18 (stable) by positron decay. the principal photons useful for imaging are the dual 511 kev "annihilation" gamma photons, that are produced and emitted simultaneously in

Ireland - English - HPRA (Health Products Regulatory Authority)

m2i limited - fludeoxyglucose (18f) - solution for injection - 1-13 gbq/ml

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - solution for injection - fludeoxyglucose 250 mbq/ml - diagnostic radiopharmaceuticals

Canada - English - Health Canada

ciuss de l'estrie - centre hospitalier universitaire de sherbrooke - fludeoxyglucose 18f - solution - 7.4gbq - fludeoxyglucose 18f 7.4gbq - roentgenography

Canada - English - Health Canada

nova scotia health authority - fludeoxyglucose 18f - solution - 200mci - fludeoxyglucose 18f 200mci - diagnostic agents

United States - English - NLM (National Library of Medicine)

kettering medical center - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures none. pregnancy category c animal reproduction studies have not been conducted with fludeoxyglucose f 18 injection. it is also not known whether fludeoxyglucose f 18 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. consider alternative diagnostic tests in a p

United States - English - NLM (National Library of Medicine)

kreitchman pet center - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none pregnancy category c animal reproduction studies have not been conducted with fludeoxyglucose f 18 injection. it is also not known whether fludeoxyglucose f 18 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. consider alternative diagnostic tests in a pregnant woman; administer fludeoxyglucose f 18 injection only if clearly needed. it is not known whether fludeoxyglucose f 18 injection is excreted in human milk. consider alternative diagnostic tests in women who are breast-feeding. use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if fludeoxyglucose f 18 injection is administered to a woman who is breast-feeding. the safety and effectiveness of fludeoxyglucose f 18 injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. in pediatric patients with epilepsy, the recommended dose is 2.6 mci. the optimal dose adjustment on the basis of body size or weight has not been determined. in the oncology or cardiology settings, the safety and effectiveness of fludeoxyglucose f 18 injection have not been established in pediatric patients.

United States - English - NLM (National Library of Medicine)

sofie co. dba sofie - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none. pregnancy category c animal reproduction studies have not been conducted with fludeoxyglucose f 18 injection. it is also not known whether fludeoxyglucose f 18 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  consider alternative diagnostic tests in a